E

Evolent

Delivers value-based care through analytics

Full-Stack AI Engineer - AI Service Engines & Integration

Full-Time
$115k - $135k
Mid, Senior
Bachelor's
Remote in USA
Remote
Software EngineeringAI Application Engineering, Backend Engineering
Company Does Not Provide H1B Sponsorship

About the job

Requirements
  • A bachelor's degree in Computer Science, Software Engineering, or a related field, or equivalent experience.
  • Three to five or more years of software engineering experience.
  • Strong Python skills and experience with at least one other modern language: TypeScript, C#, Java, or Go.
  • Experience building and consuming RESTful APIs and microservices, including message-driven and service-bus integration patterns.
  • Experience integrating large language model APIs, such as Azure OpenAI, OpenAI, or Anthropic, into applications.
  • Experience working in Agile development environments with code review, testing, and continuous integration and continuous delivery.
  • Maintain high-speed home internet over 10 Mbps.
Responsibilities
  • Design and build the adapter layer between AI service engines and the enterprise service bus, including constructing and handling FHIR PAS (Prior Authorization Support) payloads.
  • Build a synchronous service engine for real-time AI workloads, such as letter generation, adapting the architecture of the existing asynchronous Triage engine.
  • Build, deploy, and operate large language model-based agents on the service engines, managing the process of moving an agent from configuration to production.
  • Support and maintain the existing production Triage services, including bug fixes, dependency and model upgrades, releases, and operational health.
  • Integrate large language model and generative AI services, including Azure OpenAI and related services, into production business workflows.
  • Implement continuous integration and continuous delivery, automated testing, monitoring, and observability for AI services; contribute to dashboards and alerting.
  • Work within the team's architecture standards and review gates, and document completed work so others can operate it.
  • Handle clinical data, including protected health information, according to organizational security, privacy, and compliance requirements.
  • Complete government-issued photo ID verification, a comprehensive background check, and in-person I-9 verification; drug screening may also be required.
  • Attend onsite final interviews if required.
Desired Qualifications
  • FHIR experience, especially prior-authorization workflows using the PAS implementation guide or X12 278 crosswalk, or other healthcare interoperability experience such as HL7v2 or CDA.
  • Experience with agentic AI frameworks and patterns, such as pydantic-ai or LangGraph, and structured-output large language model development.
  • Experience with large language model observability and telemetry, including OpenTelemetry-based tracing, Logfire, or similar tools.
  • Azure cloud experience, including Azure AI services, Azure SQL, and containerized deployment.
  • Experience with Docker, Kubernetes, and infrastructure-as-code practices.
  • Healthcare, payer, or other regulated-domain engineering experience.

About the company

Evolent Health helps healthcare organizations transition to value-based care by pairing technology, analytics, and clinical expertise to improve patient outcomes while lowering costs. It partners with health systems, physician groups, and health plans to deliver data-driven care coordination, population health management, and risk-adjustment services. The company’s offerings include software platforms, analytics, and clinical support that enable more efficient care delivery, shared savings programs, and performance-based incentives. Compared with competitors, Evolent emphasizes end-to-end collaboration with clients and a diversified client base, combining technology with hands-on clinical and operational expertise to drive measurable outcomes. Its goal is to help clients succeed in value-based models by delivering better patient care at lower total costs.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Arlington, Virginia

Founded

2011

Get referred to Evolent

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $652.5 million, and guidance rose to $2.65 billion.
  • Highmark launched May 1, 2026, and Aetna metrics exceeded targets in Q2.
  • Management expects 2027 revenue growth above 25%, backed by renewals and oncology expansion.

What critics are saying

  • Evolent carried $966.5 million debt on June 30, 2026, squeezing refinancing flexibility.
  • Management expects a 40% exchange-membership decline in 2026, pressuring Specialty T&S revenue.
  • The $398 million 2025 goodwill impairment exposes fragile asset values if August 2026 margins weaken.

What makes Evolent unique

  • Evolent pairs oncology Performance Suite with payer integrations, spanning Highmark, Aetna, and Blue Cross.
  • Archie Mayani joined March 2026, accelerating Auth Intelligence and AI-enabled prior authorization.
  • Evolent sells risk-bearing clinical workflows, not generic software, embedding into payer economics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Flexible Work Hours
  • Hybrid Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 16th, 2026
Healthcare stocks outpace S&P 500 by 13 percentage points over six months

Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.

Yahoo Finance
Aug 15th, 2026
Evolent Health beats Q2 revenue estimates by 9.4%, raises full-year guidance to $2.65B

Evolent Health reported strong second-quarter results, beating revenue expectations with $652.5 million versus the anticipated $596.7 million, representing 46.9% year-on-year growth. The company also surpassed adjusted earnings per share and EBITDA forecasts. CEO Seth Blackley attributed the performance to successful contract launches with Highmark and robust customer renewals. Clinical engagement metrics for new partnerships with Aetna and Highmark exceeded targets, demonstrating strong execution in value-based care solutions. The company raised its full-year revenue guidance to $2.65 billion at the midpoint, up 6% from the previous $2.5 billion forecast. EBITDA guidance remained at $127.5 million. During the earnings call, management addressed analyst questions about reserving processes, margin trends in new contracts, and pipeline development. Blackley noted the business pipeline has refilled with several large national plans under consideration, particularly in oncology services.

Yahoo Finance
Aug 10th, 2026
Evolent Health beats revenue estimates with $652.5M, raises full-year guidance to $2.65B on AI automation gains

Evolent Health reported Q2 2026 revenue of $652.5 million, up 46.9% year-on-year and beating analyst estimates by 9.4%. The healthcare solutions company's full-year revenue guidance of $2.65 billion came in 5.9% above consensus. CEO Seth Blackley highlighted the successful launch of the Highmark contract and strong clinical engagement metrics for new partnerships with Aetna and Highmark. The company's Auth Intelligence automation platform contributed to operational efficiency gains. Management pointed to expansion of its oncology Performance Suite and accelerated deployment of its AI-enabled authorisation platform as key growth drivers. Blackley stated Q2 represented "a tipping point in our AI journey" as efforts moved beyond pilot phases to meaningful scale. The company expects cost-saving initiatives and improved operating leverage to offset headwinds from Medicaid and exchange membership pressures.

Yahoo Finance
Aug 6th, 2026
Evolent Health revenue surges 31% to $653M, raises 2026 guidance to $2.7B

Evolent Health reported strong second-quarter 2026 results, with total revenue reaching $653 million, up 31% from the previous quarter. Adjusted EBITDA rose 27% quarter-over-quarter to $28 million. The healthcare technology company raised its full-year 2026 revenue guidance to between $2.6 billion and $2.7 billion. It tightened adjusted EBITDA guidance to a range of $120 million to $135 million. Evolent announced a new oncology Performance Suite partnership covering approximately 1.5 million lives across 11 states, expected to generate about $300 million in annualised revenue. The company also secured a contract extension with a regional Blue Cross plan. The firm ended Q2 with $115.7 million in unrestricted cash and $808.3 million of net debt. For 2027, Evolent expects revenue growth exceeding 25%.

Yahoo Finance
Jun 12th, 2026
Evolent Health posts weakest Q1 revenue growth among healthcare tech providers despite $496M earnings

Evolent Health reported Q1 revenues of $496.2 million, up 2.6% year on year, but falling short of analysts' expectations by 6.9%. The healthcare technology company, which provides specialty care management services for patients with complex conditions, delivered mixed results with an earnings per share beat but a significant revenue miss. The healthcare technology for providers sector showed overall strength in Q1, with the four tracked stocks beating revenue consensus estimates by 1.1% on average. Share prices have risen 7.7% on average since earnings results. Despite having the weakest performance against analyst estimates and slowest revenue growth in the group, Evolent Health raised its full-year guidance the most. The stock has climbed 21.5% since reporting and currently trades at $4.65.